

## MINERVA

## Non-pulmonary presentations of mycobacteria in anti-TNF therapy

Gary Leggatt *specialist registrar in renal medicine*<sup>1</sup>, Catherine Sargent *consultant in acute medicine*<sup>2</sup>,  
Melanie Newport *professor of infectious diseases and global health*<sup>3</sup>

<sup>1</sup>Department of Renal Medicine, Royal London Hospital, London, UK; <sup>2</sup>Department of Acute Medicine, Brighton Sussex University NHS Trust, Brighton BN2 5BE, UK ; <sup>3</sup>Division of Clinical Medicine, Brighton Sussex Medical School, Brighton, UK



a non-blanching violaceous rash on his shins and a swollen tender wrist. He was being treated with infliximab and parenteral nutrition. *Mycobacterium chelonae* was isolated from a wrist aspirate and multiple blood cultures. His lungs were not affected. He responded well to amikacin, moxifloxacin, and clarithromycin for disseminated infection. The Medicines and Healthcare Products Regulatory Agency reports four such cases of rapidly growing mycobacteria associated with anti-tumour necrosis factor (TNF) treatment. Clinicians should be aware that patients taking anti-TNF agents may present with extrapulmonary manifestations only.

Patient consent obtained.

Cite this as: *BMJ* 2014;348:g3708

© BMJ Publishing Group Ltd 2014

A 33 year old man with Crohn's disease presented with fever and erythema around his tunnelled central line. He developed